Aclaris Therapeutics (NASDAQ:ACRS - Get Free Report) released its quarterly earnings results on Thursday. The biotechnology company reported ($0.10) earnings per share for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.01), Zacks reports. Aclaris Therapeutics had a negative net margin of 136.65% and a negative return on equity of 40.26%. The business had revenue of $9.21 million for the quarter, compared to the consensus estimate of $7.04 million.
Aclaris Therapeutics Stock Performance
NASDAQ ACRS traded down $0.03 on Monday, reaching $1.96. The company's stock had a trading volume of 547,594 shares, compared to its average volume of 772,062. Aclaris Therapeutics has a twelve month low of $0.95 and a twelve month high of $5.17. The firm's 50 day moving average is $2.42 and its two-hundred day moving average is $2.17. The stock has a market cap of $140.00 million, a PE ratio of -3.77 and a beta of 0.50.
Analysts Set New Price Targets
Several analysts have weighed in on the company. Leerink Partnrs raised Aclaris Therapeutics from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, November 19th. Piper Sandler upgraded shares of Aclaris Therapeutics from a "neutral" rating to an "overweight" rating and lifted their price objective for the company from $3.00 to $13.00 in a research note on Monday, November 18th. Jefferies Financial Group raised shares of Aclaris Therapeutics from a "hold" rating to a "buy" rating and upped their price objective for the stock from $2.00 to $7.00 in a report on Tuesday, November 19th. StockNews.com cut shares of Aclaris Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, February 8th. Finally, BTIG Research raised shares of Aclaris Therapeutics from a "neutral" rating to a "buy" rating and set a $8.00 price target for the company in a research note on Tuesday, November 19th. One investment analyst has rated the stock with a sell rating, five have given a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Buy" and an average target price of $11.00.
View Our Latest Research Report on Aclaris Therapeutics
Aclaris Therapeutics Company Profile
(
Get Free Report)
Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.
Featured Articles
Before you consider Aclaris Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aclaris Therapeutics wasn't on the list.
While Aclaris Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
